{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:17:02Z","timestamp":1772075822804,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01951-1","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:23:44Z","timestamp":1756297424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing long term disease prevention with reinforcement learning: a framework for precision lipid control"],"prefix":"10.1038","volume":"8","author":[{"given":"Yekai","family":"Zhou","sequence":"first","affiliation":[]},{"given":"Ruibang","family":"Luo","sequence":"additional","affiliation":[]},{"given":"Joseph Edgar","family":"Blais","sequence":"additional","affiliation":[]},{"given":"Kathryn C. B.","family":"Tan","sequence":"additional","affiliation":[]},{"given":"David Tak Wai","family":"Lui","sequence":"additional","affiliation":[]},{"given":"Kai Hang","family":"Yiu","sequence":"additional","affiliation":[]},{"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[]},{"given":"Eric Yuk Fai","family":"Wan","sequence":"additional","affiliation":[]},{"given":"Ching-Lung","family":"Cheung","sequence":"additional","affiliation":[]},{"given":"Ian CK","family":"Wong","sequence":"additional","affiliation":[]},{"given":"Celine SL","family":"Chui","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"1951_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204\u20131222 (2020).","journal-title":"Lancet"},{"key":"1951_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrg.2016.86","volume":"17","author":"EA Ashley","year":"2016","unstructured":"Ashley, E. A. Towards precision medicine. Nat. Rev. Genet. 17, 507\u2013522 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"1951_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41551-018-0305-z","volume":"2","author":"KH Yu","year":"2018","unstructured":"Yu, K. H., Beam, A. L. & Kohane, I. S. Artificial intelligence in healthcare. Nat. Biomed. Eng. 2, 719\u2013731 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1951_CR4","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr.","year":"2014","unstructured":"Goff, D. C. Jr. et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63, 2935\u20132959 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1951_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. heart J."},{"key":"1951_CR6","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596\u2013e646 (2019).","journal-title":"Circulation"},{"key":"1951_CR7","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FL Visseren","year":"2021","unstructured":"Visseren, F. L. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur. heart J. 42, 3227\u20133337 (2021).","journal-title":"Eur. heart J."},{"key":"1951_CR8","unstructured":"World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk, (World Health Organization, 2007)."},{"key":"1951_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and Validation of the American Heart Association\u2019s PREVENT Equations. Circulation 149, 430\u2013449 (2024).","journal-title":"Circulation"},{"key":"1951_CR10","doi-asserted-by":"crossref","unstructured":"group, S.w. & collaboration, E.S.C.C.r SCORE2 risk prediction algorithms: new models to estimate 10-year risk ofcardiovascular disease in Europe. Eur. Heart J. 42, 2439\u20132454 (2021).","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"1951_CR11","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357, j2099 (2017).","journal-title":"BMJ"},{"key":"1951_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/S0140-6736(18)30664-0","volume":"391","author":"R Pylypchuk","year":"2018","unstructured":"Pylypchuk, R. et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 391, 1897\u20131907 (2018).","journal-title":"Lancet"},{"key":"1951_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0002-9149(76)90061-8","volume":"38","author":"WB Kannel","year":"1976","unstructured":"Kannel, W. B., McGee, D. & Gordon, T. A general cardiovascular risk profile: the Framingham Study. Am. J. Cardiol. 38, 46\u201351 (1976).","journal-title":"Am. J. Cardiol."},{"key":"1951_CR14","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin, S. S. et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation 149, e347\u2013e913 (2024).","journal-title":"Circulation"},{"key":"1951_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/eurheartj\/ehae302","volume":"45","author":"KA Krychtiuk","year":"2024","unstructured":"Krychtiuk, K. A., Gersh, B. J., Washam, J. B. & Granger, C. B. When cardiovascular medicines should be discontinued. Eur. Heart J. 45, 2039\u20132051 (2024).","journal-title":"Eur. Heart J."},{"key":"1951_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41591-018-0310-5","volume":"25","author":"O Gottesman","year":"2019","unstructured":"Gottesman, O. et al. Guidelines for reinforcement learning in healthcare. Nat. Med 25, 16\u201318 (2019).","journal-title":"Nat. Med"},{"key":"1951_CR17","unstructured":"Sutton, R. S. & Barto, A. G. Reinforcement learning: An introduction, (MIT press, 2018)."},{"key":"1951_CR18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41591-023-02475-5","volume":"29","author":"C Barata","year":"2023","unstructured":"Barata, C. et al. A reinforcement learning model for AI-based decision support in skin cancer. Nat. Med 29, 1941\u20131946 (2023).","journal-title":"Nat. Med"},{"key":"1951_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41586-021-04014-z","volume":"599","author":"H Bastani","year":"2021","unstructured":"Bastani, H. et al. Efficient and targeted COVID-19 border testing via reinforcement learning. Nature 599, 108\u2013113 (2021).","journal-title":"Nature"},{"key":"1951_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41591-021-01599-w","volume":"28","author":"A Yala","year":"2022","unstructured":"Yala, A. et al. Optimizing risk-based breast cancer screening policies with reinforcement learning. Nat. Med 28, 136\u2013143 (2022).","journal-title":"Nat. Med"},{"key":"1951_CR21","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/s41591-023-02552-9","volume":"29","author":"G Wang","year":"2023","unstructured":"Wang, G. et al. Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial. Nat. Med 29, 2633\u20132642 (2023).","journal-title":"Nat. Med"},{"key":"1951_CR22","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41591-018-0213-5","volume":"24","author":"M Komorowski","year":"2018","unstructured":"Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C. & Faisal, A. A. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat. Med 24, 1716\u20131720 (2018).","journal-title":"Nat. Med"},{"key":"1951_CR23","unstructured":"Hong Kong Hospital Authority. Data Collaboration Lab (Pilot). (2019)."},{"key":"1951_CR24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law, M. R., Wald, N. J. & Rudnicka, A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423 (2003).","journal-title":"BMJ"},{"key":"1951_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.artmed.2012.12.003","volume":"57","author":"CC Bennett","year":"2013","unstructured":"Bennett, C. C. & Hauser, K. Artificial intelligence framework for simulating clinical decision-making: a Markov decision process approach. Artif. Intell. Med 57, 9\u201319 (2013).","journal-title":"Artif. Intell. Med"},{"key":"1951_CR26","unstructured":"Bertsekas, D. Dynamic programming and optimal control: Volume I, (Athena scientific, 2012)."},{"key":"1951_CR27","unstructured":"Levine, S., Kumar, A., Tucker, G. & Fu, J. Offline reinforcement learning: Tutorial, review, and perspectives on open problems. arXiv preprint arXiv:2005.01643 (2020)."},{"key":"1951_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1561\/2200000086","volume":"16","author":"TM Moerland","year":"2023","unstructured":"Moerland, T. M., Broekens, J., Plaat, A. & Jonker, C. M. Model-based reinforcement learning: A survey. Found. Trends\u00ae Mach. Learn. 16, 1\u2013118 (2023).","journal-title":"Found. Trends\u00ae Mach. Learn."},{"key":"1951_CR29","doi-asserted-by":"publisher","first-page":"e0322419","DOI":"10.1371\/journal.pone.0322419","volume":"20","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y. et al. Primary Prevention Cardiovascular Disease Risk Prediction Model for Contemporary Chinese (1\u00b0 P-CARDIAC):Model Derivation and Validation Using a Hybrid Statistical and Machine-Learning Approach. PLoS One 20, e0322419 (2025).","journal-title":"PLoS One"},{"key":"1951_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/ehjdh\/ztae018","volume":"5","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Development and validation of risk prediction model for recurrent cardiovascular events among Chinese: the Personalized CARdiovascular DIsease risk Assessment for Chinese model. Eur. Heart J.- Digital Health 5, 363\u2013370 (2024).","journal-title":"Eur. Heart J.- Digital Health"},{"key":"1951_CR31","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Development and validation of a tool to stratify the treatment effect of low-dose aspirin in patients with cardiovascular disease: VISTA (Vascular Intervention Stratification Tool for Aspirin). medRxiv, 2024.2006.2007.24308636 (2024).","DOI":"10.1101\/2024.06.07.24308636"},{"key":"1951_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3477600","volume":"55","author":"C Yu","year":"2021","unstructured":"Yu, C., Liu, J., Nemati, S. & Yin, G. Reinforcement learning in healthcare: A survey. ACM Comput. Surv. (CSUR) 55, 1\u201336 (2021).","journal-title":"ACM Comput. Surv. (CSUR)"},{"key":"1951_CR33","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383\u20131389 (1994).","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"1951_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"HTC Group","year":"2014","unstructured":"Group, H. T. C. et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med 371, 203\u2013212 (2014).","journal-title":"N. Engl. J. Med"},{"key":"1951_CR35","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med 359, 2195\u20132207 (2008).","journal-title":"N. Engl. J. Med"},{"key":"1951_CR36","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181\u20132192 (2011).","journal-title":"Lancet"},{"key":"1951_CR37","first-page":"1001","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholest. Recurr. Events Trial investigators. N. Engl. J. Med 335, 1001\u20131009 (1996).","journal-title":"Cholest. Recurr. Events Trial investigators. N. Engl. J. Med"},{"key":"1951_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41591-018-0320-3","volume":"25","author":"B Norgeot","year":"2019","unstructured":"Norgeot, B., Glicksberg, B. S. & Butte, A. J. A call for deep-learning healthcare. Nat. Med 25, 14\u201315 (2019).","journal-title":"Nat. Med"},{"key":"1951_CR39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nbt.4233","volume":"36","author":"M Wainberg","year":"2018","unstructured":"Wainberg, M., Merico, D., Delong, A. & Frey, B. J. Deep learning in biomedicine. Nat. Biotechnol. 36, 829\u2013838 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1951_CR40","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/bib\/bbx044","volume":"19","author":"R Miotto","year":"2018","unstructured":"Miotto, R., Wang, F., Wang, S., Jiang, X. & Dudley, J. T. Deep learning for healthcare: review, opportunities and challenges. Brief. Bioinform 19, 1236\u20131246 (2018).","journal-title":"Brief. Bioinform"},{"key":"1951_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436\u2013444 (2015).","journal-title":"Nature"},{"key":"1951_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","volume":"25","author":"A Esteva","year":"2019","unstructured":"Esteva, A. et al. A guide to deep learning in healthcare. Nat. Med 25, 24\u201329 (2019).","journal-title":"Nat. Med"},{"key":"1951_CR43","doi-asserted-by":"crossref","unstructured":"Amershi, S. et al. Guidelines for Human-AI Interaction. in Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems Paper 3 (Association for Computing Machinery, Glasgow, Scotland Uk, 2019).","DOI":"10.1145\/3290605.3300233"},{"key":"1951_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41591-024-02917-8","volume":"30","author":"AYL Chan","year":"2024","unstructured":"Chan, A. Y. L. et al. Maternal diabetes and risk of attention-deficit\/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother-child pairs. Nat. Med 30, 1416\u20131423 (2024).","journal-title":"Nat. Med"},{"key":"1951_CR45","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7326\/M24-0004","volume":"177","author":"W Xu","year":"2024","unstructured":"Xu, W., Lee, A. L., Lam, C. L. K., Danaei, G. & Wan, E. Y. F. Benefits and Risks Associated With Statin Therapy for Primary Prevention in Old and Very Old Adults : Real-World Evidence From a Target Trial Emulation Study. Ann. Intern Med 177, 701\u2013710 (2024).","journal-title":"Ann. Intern Med"},{"key":"1951_CR46","doi-asserted-by":"publisher","first-page":"h6926","DOI":"10.1136\/bmj.h6926","volume":"352","author":"AY Wong","year":"2016","unstructured":"Wong, A. Y. et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 352, h6926 (2016).","journal-title":"BMJ"},{"key":"1951_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression Models and Life-Tables. J. R. Stat. Soc. Ser. B (Methodol.) 34, 187\u2013220 (1972).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"1951_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression Shrinkage and Selection Via the Lasso. J. R. Stat. Soc.: Ser. B (Methodol 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc.: Ser. B (Methodol"},{"key":"1951_CR49","unstructured":"Lundberg, S. M. & Lee, S.-I. A unified approach to interpreting model predictions. Adv. Neural Info. Processing Syst. 30, (2017)."},{"key":"1951_CR50","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1109\/TNNLS.2015.2503980","volume":"28","author":"DP Bertsekas","year":"2017","unstructured":"Bertsekas, D. P. Value and Policy Iterations in Optimal Control and Adaptive Dynamic Programming. IEEE Trans. Neural Netw. Learn Syst. 28, 500\u2013509 (2017).","journal-title":"IEEE Trans. Neural Netw. Learn Syst."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01951-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:45:12Z","timestamp":1757479512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01951-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1951"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01951-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.Y.F.W. has received research grants from the Health Bureau, the Hong Kong Research Grants Council, Narcotics Division, Security Bureau, Social Welfare Department, Labour and Welfare Bureau of the Government of the Hong Kong SAR and National Natural Science Foundation of China; serves on member of Core Team for Expert Group on Drug Registration of Pharmacy and Poisons Board, and is the director of Advance Data Analytics for Medical Science (ADAMS) Limited (HK); outside the submitted work. F.T.T.L. has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council and has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region, outside the submitted work. I.C.K.W. has received research grants from Amgen, Janssen, GSK, Novartis, Pfizer, Bayer and Bristol-Myers Squibb and Takeda, Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, The European Union's Seventh Framework Programme for research, technological development, Research Grants Council Hong Kong and Health and Medical Research Fund Hong Kong; consulting fee from IQVIA and WHO; payment for expert testimony for Appeal Court in Hong Kong; serves on advisory committees for Member of Pharmacy and Poisons Board; Member of the Expert Committee on Clinical Events Assessment Following COVID-19 Immunization; Member of the Advisory Panel on COVID-19 Vaccines of the Hong Kong Government; is the non-executive director of Jacobson Medical in Hong Kong; is the Founder and Director of Therakind Limited (UK), ADAMS Limited (HK), Asia Medicine Regulatory Affairs (AMERA) Services Limited and OCUS Innovation Limited (HK, Ireland and UK). C.L.C. received research grants and the honorarium from Amgen, research grant support from HMRF, and the honorarium from Abbott. C.S.L.C. has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen; and personal fees from PrimeVigilance and MSD; outside the submitted work. R.L. has received grants from Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission; and research donations from Oxford Nanopore Technologies, outside the submitted work. K.C.B.T. received consulting or speaker fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk and Sanofi. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval for this study was granted by the Institutional Review Board of The University of Hong Kong\/HA Hong Kong West Cluster (UW20-073). Informed consent is waived by IRB in view of the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"553"}}